PHAXIAM Therapeutics Shares Promising Results in Latest Study
Regulatory news from PHAXIAM Therapeutics, a biopharmaceutical company dedicated to developing innovative treatments for difficult bacterial infections, reveals an encouraging update regarding the clinical data from patients treated with the company's unique phage therapies.
Significant Clinical Findings
Since 2017, PHAXIAM has provided compassionate treatment to over 120 patients suffering predominantly from prosthetic joint infections (PJI) associated with hip or knee implants. While most treatments have taken place in France, the expanding reach of PHAXIAM's therapy is being recognized across various European nations.
Proven Effectiveness at Three Months
The initial evaluation of 88 patients highlighted a remarkable 75% infection control rate at three months, showcasing significant advancements over standard treatments for patients dealing with severe relapsing infections, often complicated by antimicrobial resistance.
Of the patients studied, 52 were diagnosed with PJIs primarily caused by Staphylococcus aureus (n=40) or Pseudomonas aeruginosa (n=12), achieving an impressive overall control rate of 79%. Specifically, the control rate for the S. aureus subgroup reached 77%, while a noteworthy 83% was observed in patients infected with P. aeruginosa.
Ongoing Monitoring Shows Sustained Efficacy
While comprehensive data for 12-month outcomes are still being collected, preliminary findings indicate that infection control remains very high, ranging between 64% and 67%. These statistics are particularly promising for this complex group of patients.
Pathway to Future Trials
The recent clinical results provide a strong rationale for launching the GLORIA Phase II proof-of-concept trial. This trial aims to further validate the safety and effectiveness of PHAXIAM’s innovative phage therapies.
Broadening Treatment Scope
Alongside PJIs, PHAXIAM is investigating other severe infections like osteomyelitis and vascular infections, which include endocarditis and cardiac implant infections. The company is also exploring various administration routes such as local, intravenous, and nebulization, all of which have shown to be well-tolerated by patients.
Pioneering Compassionate Treatment Programs
PHAXIAM's initiatives include the “PHAGEinLYON Clinic” program backed by the Fondation Hospices Civils de Lyon, facilitating over half of the compassionate treatments administered.
The company has received an authoritative compassionate access program, AAC, designation for its S. aureus phages that it plans to leverage to gain similar approval for dealing with resistant P. aeruginosa infections by early 2025. Through these efforts, PHAXIAM is committed to expanding access to their innovative therapies.
Insights from Medical Leaders
Dr. Pascal Birman, Chief Medical Officer of PHAXIAM, expressed confidence in the data, affirming their clinical strategy’s relevance emphasizing high-value indications like PJI, which can facilitate significant clinical benefits for patients.
Pr. Tristan Ferry, Director of the Reference Center for Managing Complex Bone and Joint Infections at Hôpital de la Croix-Rousse, lauded the importance of phage therapy for patients with complex infections that resist standard treatments. His team is increasingly engaging in multidisciplinary evaluations to identify suitable candidates for compassionate treatment.
About CRIOAC Lyon
The Centre de Référence des Infections Ostéo-articulaires Complexes (CRIOAC) provides essential multidisciplinary care for complex osteoarticular infections, offering the required expertise for effective medical and surgical interventions.
About PHAXIAM Therapeutics
PHAXIAM focuses on crafting cutting-edge treatments for resistant bacterial infections using phages, the natural viruses that kill bacteria. The company has developed a diverse portfolio targeting three notoriously resistant bacteria, which contribute to a significant percentage of hospital-acquired infections.
PHAXIAM is publicly traded on the Euronext regulated market in Paris and is part of numerous indices, including CAC Healthcare and CAC Pharma & Bio.
Frequently Asked Questions
What is PHAXIAM Therapeutics known for?
PHAXIAM Therapeutics specializes in developing innovative therapies for severe and resistant bacterial infections using phage technology.
What clinical data was recently announced by PHAXIAM?
PHAXIAM announced promising results for its phage therapy treatment, demonstrating a 75% infection control rate at three months for patients treated under compassionate use.
Where does PHAXIAM conduct its clinical treatments?
PHAXIAM primarily treats patients in France but is expanding its compassionate use therapy across other European countries.
What are the future plans for PHAXIAM's research?
The company aims to advance its GLORIA Phase II proof-of-concept trial and expand its treatment options to include resistant bacterial infections.
How does PHAXIAM support its clinical programs?
PHAXIAM's programs are supported by collaborations with local hospitals and initiatives designed to access innovative treatment options for patients.
